Brown, Lisle/Cummings’s GSK GSK Stock Holding History

Brown, Lisle/Cummings’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.2K	Hold	293	–	–	﹤0.01%	498
2025 Q4	$14.4K	Hold	293	–	–	﹤0.01%	461
2025 Q3	$12.6K	Hold	293	–	–	﹤0.01%	478
2025 Q2	$11.3K	Buy	293 +1	+0.3%	+$38	﹤0.01%	490
2025 Q1	$11.3K	Sell	292 -308	-51%	-$11.3K	﹤0.01%	481
2024 Q4	$20.3K	Hold	600	–	–	0.01%	417
2024 Q3	$24.5K	Sell	600 -332	-36%	-$13.6K	0.01%	369
2024 Q2	$35.9K	Sell	932 -1,044	-53%	-$43.9K	0.01%	339
2024 Q1	$84.7K	Sell	1,976 -5,389	-73%	-$222K	0.03%	252
2023 Q4	$273K	Buy	7,365 +238	+3%	+$8.54K	0.1%	173
2023 Q3	$258K	Sell	7,127 -1,242	-15%	-$44.1K	0.12%	160
2023 Q2	$298K	Sell	8,369 -870	-9%	-$31.2K	0.13%	149
2023 Q1	$329K	Buy	9,239 +1,010	+12%	+$35.3K	0.17%	131
2022 Q4	$289K	Sell	8,229 -1,741	-17%	-$58K	0.16%	127
2022 Q3	$293K	Buy	9,970 +1,900	+24%	+$72K	0.17%	121
2022 Q2	$439K	Buy	8,070 +14	+0.2%	+$773	0.24%	99
2022 Q1	$439K	Buy	8,056 +274	+4%	+$14.9K	0.21%	109
2021 Q4	$429K	Buy	+7,782	New	+$405K	0.21%	107

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Brown, Lisle/Cummings's GSK Position: Q1 2026 in Review

Brown, Lisle/Cummings held its GSK (GSK) position steady in Q1 2026 at 293 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #498.

Brown, Lisle/Cummings first reported a position in GSK in Q4 2021 and has held it in 18 quarters since. The position peaked at $439K in Q2 2022. 1,035 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Brown, Lisle/Cummings held 293 shares of GSK worth $16.2K as of Q1 2026.
Brown, Lisle/Cummings left its GSK share count unchanged in Q1 2026.
GSK made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #498 holding.
Brown, Lisle/Cummings first reported a position in GSK in Q4 2021 and has held it in 18 quarters since.
Brown, Lisle/Cummings's GSK position peaked at $439K in Q2 2022.
1,035 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.